Zu den Inhalten springen
Universitäts-Herzzentrum Freiburg - Bad KrozingenUniversitäts-Herzzentrum Freiburg - Bad Krozingen


AG Thrombozyten und Atherothrombose


Rivaroxaban for stroke prevention in atrial fibrillation and secondary prevention in patients with a recent acute coronary syndrome.
Ahrens I, Bode C.
Future Cardiol. 2012 Jul;8(4):533-41.

Oral anticoagulation with edoxaban. Focus on current phase III clinical development.
Ahrens I, Bode C.
Hämostaseologie. 2012 Jul 12;32(3).

Development and clinical applications of novel oral anticoagulants. Part II. Drugs under clinical investigation.
Ahrens I, Peter K, Lip GY, Bode C.
Discov Med. 2012 Jun;13(73):445-50.

Development and clinical applications of novel oral anticoagulants. Part I. Clinically approved drugs.
Ahrens I, Peter K, Lip GY, Bode C.
Discov Med. 2012 Jun;13(73):433-43.

Novel single-chain antibody-targeted microbubbles for molecular ultrasound imaging of thrombosis: validation of a unique noninvasive method for rapid and sensitive detection of thrombi and monitoring of success or failure of thrombolysis in mice.
Wang X, Hagemeyer CE, Hohmann JD, Leitner E, Armstrong PC, Jia F, Olschewski M, Needles A, Peter K, Ahrens I.
Circulation. 2012 Jun 26;125(25):3117-26.

New Parenteral Anticoagulants: Focus on Factor Xa and Thrombin Inhibitors.
Ahrens I, Bode C.
Curr Drug Discov Technol. 2012 Jun 1;9(2):129-36.

Serotonin antagonism improves platelet inhibition in clopidogrel low-responders after coronary stent placement: an in vitro pilot study.
Duerschmied D, Ahrens I, Mauler M, Brandt C, Weidner S, Bode C, Moser M.
PLoS One. 2012;7(2):e32656. Epub 2012 Feb 27.

Successful in vitro expansion and differentiation of cord blood derived CD34+ cells into early EPCs reveals highly differential gene expression.
Ahrens I, Domeij H, Topcic D, Haviv I, Merivirta R-M, Agrotis A, Leitner E, Jowett JB, Bode C, Lappas M, Peter K.
PLoS One. 2011;6(8):e23210.

Measuring oxidative burden and predicting pharmacological response in coronary artery disease patients with a novel direct activator of haem-free/oxidised sGC.
Ahrens I, Habersberger J, Baumlin N, Qian H, Smith BK, Stasch J-P, Bode C, Schmidt HHHW, Peter K.
Atherosclerosis. 2011 Oct;218(2):431-4.

Opposing effects of monomeric and pentameric C-reactive protein on endothelial progenitor cells.
Ahrens I, Domeij H, Eisenhardt SU, Topcic D, Albrecht M, Leitner E, Viitaniemi K, Jowett JB, Lappas M, Bode C, Haviv I, Peter K.
Basic Res Cardiol. 2011 Sep;106(5):879-95.

GPVI and GPIbα mediate staphylococcal superantigen-like protein 5 (SSL5) induced platelet activation and direct toward glycans as potential inhibitors.
Hu H, Armstrong PC, Khalil E, Chen YC, Straub A, Li M, Soosairajah J, Hagemeyer CE, Bassler N, Huang D, Ahrens I, Krippner G, Gardiner E, Peter K.
PLoS One. 2011 Apr 28;6(4):e19190.

What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?
Ahrens I, Lip GY, Peter K.
Thromb Haemost. 2011 Apr;105(4):574-8.

High-mobility group box protein 1 neutralization reduces development of diet-induced atherosclerosis in apolipoprotein e-deficient mice.
Kanellakis P, Agrotis A, Kyaw TS, Koulis C, Ahrens I, Mori S, Takahashi HK, Liu K, Peter K, Nishibori M, Bobik A.
Arterioscler Thromb Vasc Biol. 2011 Feb;31(2):313-9

New oral anticoagulant drugs in cardiovascular disease.
Ahrens I, Lip GY, Peter K.
Thromb Haemost. 2010 Jul 5;104(1):49-60

Genetic transfer of fusion proteins effectively inhibits VCAM-1-mediated cell adhesion and transmigration via inhibition of cytoskeletal anchorage.
Hagemeyer CE*, Ahrens I*, Bassler N, Dschachutaschwili N, Chen YC, Eisenhardt SU, Bode C, Peter K. *these authors contributed equally
J Cell Mol Med. 2010 Jan;14(1-2):290-302.

Novel antiplatelet therapies following percutaneous coronary interventions.
Ahrens I, Bode C.
Curr Opin Investig Drugs. 2009 Sep;10(9):902-11.

FX-06, a fibrin-derived Bbeta15-42 peptide for the potential treatment of reperfusion injury following myocardial infarction.
Ahrens I, Peter K.
Curr Opin Investig Drugs. 2009 Sep;10(9):997-1003.

Dissociation of Pentameric to Monomeric C-Reactive Protein on Activated Platelets Localizes Inflammation to Atherosclerotic Plaques.
Eisenhardt SU, Habersberger J, Murphy A, Chen YC, Woollard KJ, Bassler N, Qian H, von Zur Muhlen C, Hagemeyer CE, Ahrens I, Chin-Dusting J, Bobik A, Peter K.
Circ Res. 2009 Jun 11.

Selenium supplementation induces metalloproteinase-dependent L-selectin shedding from monocytes.
Ahrens I, Ellwanger C, Smith BK, Bassler N, Chen YC, Neudorfer I, Ludwig A, Bode C, Peter K.
J Leukoc Biol. 2008 Jun;83(6):1388-95

Functionalized magnetic resonance contrast agent selectively binds to glycoprotein IIb/IIIa on activated human platelets under flow conditions and is detectable at clinically relevant field strengths.
von Zur Muhlen C, von Elverfeldt D, Choudhury RP, Ender J, Ahrens I, Schwarz M, Hennig J, Bode C, Peter K.
Mol Imaging. 2008 Mar-Apr;7(2):59-67.

Therapeutic integrin inhibition: allosteric and activation-specific inhibition strategies may surpass the initial ligand-mimetic strategies.
Ahrens I, Peter K.
Thromb Haemost. 2008 May;99(5):803-4

Humanizing mouse thrombi.
Ahrens I, Peter K.
Nat Biotechnol. 2008 Jan;26(1):62-3.

Factor Xa-inhibition in interventional cardiology
Ahrens I, Peter K, Bode C.
Hamostaseologie. 2007 Dec;27(5):328-32.

Direct thrombin inhibition with bivalirudin as an antithrombotic strategy in general and interventional cardiology.
Ahrens I, Smith BK, Bode C, Peter K.
Expert Opin Drug Metab Toxicol. 2007 Aug;3(4):609-20.

CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1.
Zirlik A, Maier C, Gerdes N, MacFarlane L, Soosairajah J, Bavendiek U, Ahrens I, Ernst S, Bassler N, Missiou A, Patko Z, Aikawa M, Schönbeck U, Bode C, Libby P, Peter K.
Circulation, 2007 Mar 27;115(12):1571-80

Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation.
Stoll P, Bassler N, Hagemeyer CE, Eisenhardt SU, Chen YC, Schmidt R, Schwarz M, Ahrens I, Katagiri Y, Pannen B, Bode C, Peter K.
Arterioscler Thromb Vasc Biol. 2007 May;27(5):1206-12

A mechanistic model for paradoxical platelet activation by ligand-mimetic alphaIIb beta3 (GPIIb/IIIa) antagonists.
Bassler N, Loeffler C, Mangin P, Yuan Y, Schwarz M, Hagemeyer CE, Eisenhardt SU, Ahrens I, Bode C, Jackson SP, Peter K.
Arterioscler Thromb Vasc Biol. 2007 Mar;27(3):e9-15.

Tiefe Beinvenenthrombosen. Diagnose und Therapie (CME Artikel)
Ahrens I, Bode C.
Internistische Praxis 47, 59-71 (2007)

Therapeutic inhibitors of platelet aggregation - from aspirin to integrin blockers.
Ahrens I, Schwarz M, Peter K, Bode C.
Transfusion Medicine and Hemotherapy 2007;34 (1): 44-54

A novel functional role for the highly conserved alpha-subunit KVGFFKR motif distinct from integrin alphaIIbbeta3 activation processes.
Aylward K, Meade G, Ahrens I, Devocelle M, Moran N.
J Thromb Haemost. 2006 Aug;4(8):1804-12

Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets.
Schwarz M, Meade G, Stoll P, Ylanne J, Bassler N, Chen YC, Hagemeyer CE, Ahrens I, Moran N, Kenny D, Fitzgerald D, Bode C, Peter K.
Circ Res. 2006 Jul 7;99(1):25-33

Therapy of acute myocardial infarction: COMMIT (Clopidogrel and Metoprolol Infarction Trial)
Ahrens I, Bode C.
Internist (Berl). 2006 Jul;47(7):764-6.

Inhibition of platelet aggregation for the secondary prevention after ACS: when clopidogrel instead of ASA, when clopidogrel and ASA?
Klaus T, Ahrens I, Bode C.
Hämostaseologie. 2006 Jan;26(1):55-8.

Evidence for a differential functional regulation of the two β3-integrins αVβ3 and αIIbβ3.
Ahrens I, IG; Moran N; Aylward K; Meade G; Moser M; Assefa D, Fitzgerald DJ; Bode C; Peter K. Experimental Cell Research, 2006 Apr 1;312(6):925-37

Inhibition of Platelet Activation and Aggregation
Ahrens I, Bode C, Peter K.
Handb Exp Pharmacol. 2005;(170):443-62

Direct Inhibition of Thrombin. A New Strategy for the Treatment of Atrial Fibrillation and Acute Coronary Syndrome?
Ahrens I, Bode C
Herz. 2005 May;30(3)

Distinct Roles of Ligand Affinity and Cytoskeletal Anchorage in IIb3 (GP IIb/IIIa)-Mediated Cell Aggregation and Adhesion
Peter K, Ahrens I, Schwarz M, Bode C, Ylänne J.
Platelets. 2004 Nov;15(7):427-38.

Use of GPIIb/IIIa inhibitors in cardiovascular medicine
Ahrens I, Peter K & Bode C
Expert Rev. Cardiovascular Ther. 1(2), 233–242 (2003)

Adhesion of monocytes to medical steel as used for vascular stents is mediated by the integrin receptor Mac-1 (CD11b/CD18; alphaM beta2) and can be inhibited by semiconductor coating.
Schuler P, Assefa D, Ylanne J, Basler N, Olschewski M, Ahrens I, Nordt T, Bode C, Peter K.
Cell Commun Adhes. 2003 Jan-Feb;10(1):17-26

Glykoprotein-IIb/IIIa-Antagonisten - Ist eine Differentialtherapie denkbar ?
Ahrens I, Peter K, Bode C.
Arzneimitteltherapie 2002;20:82-87


PD Dr. Ingo Ahrens

Telefon: +49 761 270-70470
Telefax: +49 761 270-70450